In a significant step toward closing the gap in Alzheimer’s detection, Dr. Arjun Dang announced the launch of Dendrite Dx, an integrated ecosystem for, non-invasive Alzheimer's diagnosis on World Alzheimer's Day. Designed to bridge the diagnostic gap, Dendrite Dx combines digital cognitive assessments, advanced blood biomarkers, and confirmatory proprietary LC-MS testing to deliver accessibility, accuracy, and affordability in brain health diagnostics, a release said.
The platform offers a unique, stepwise approach to screening and diagnosis — starting with a 15–20 minute digital brain cognitive assessment can be taken by anyone using a smartphone, laptop, or computer. The assessment involves simple questions and puzzles and generates a Brain Age Score along with a risk profile for cognitive decline.
For individuals with elevated risk, Dendrite Dx enables a follow-up blood test that measures FDA-approved biomarkers such as P-Tau217 and Amyloid Beta 1-42 — critical indicators for Alzheimer’s. The platform also offers APOE genotype testing to assess a person’s genetic predisposition.
If results from these steps indicate a higher probability of Alzheimer’s, patients are recommended for PrecivityAD2™ testing — a highly advanced blood-based diagnostic developed in collaboration with C2N Diagnostics, USA. This proprietary test provides an Alzheimer’s Probability Score, helping clinicians make an accurate, timely diagnosis.
Speaking at the launch, Dr. Arjun Dang highlighted the importance of early detection:
“The biggest challenge in Alzheimer’s care is that most cases are diagnosed too late. Dendrite Dx is designed to empower individuals and clinicians to act early, plan better, and explore treatment options before the disease progresses.”
Medical experts believe that the launch of Dendrite Dx could transform how Alzheimer’s is diagnosed in India by making it accessible, non-invasive, and data-driven. Early detection not only improves the chances of timely intervention but also allows families to make informed decisions, seek care options, and participate in clinical trials that can improve patient outcomes.
With its integration of digital tools, biomarkers, and genetic insights, Dendrite Dx marks a major step forward in the fight against dementia — bringing hope to millions at risk of Alzheimer’s.